La recommandation du CHMP de l’EMA est basée sur les résultats d’un essai clinique de phase 3 (GEMSTONE-302) démontrant des bénéfices significatifs en termes de survie sans progression (SSP) et de survie globale (SG) du sugemalimab en association avec la chimiothérapie en tant que…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.